Skip to content

Healthy Adults Needed for Beryllium Disease Study

Search Clinical Trials

Trial Objectives


Chronic beryllium disease (CBD) is caused by inhaling beryllium dust and fumes into the lungs. People with exposure can develop a response to beryllium similar to an allergy which can lead to scars in the lungs and breathing problems.

The goal of this study is to understand how certain white blood cells called macrophages function in the development of CBD. By collecting lung and blood samples from healthy adults, our researchers can learn more about the cells involved in the development of scarring lung diseases and ultimately target new treatment therapies.

Who Can Participate


Healthy, nonsmoking adults with no prior history of respiratory or autoimmune disease who are able to undergo a blood draw and a bronchoscopy.

Age: 18-80 Gender Any

Estimated Time Commitment


5 hours over 2 visits

Time Commitment Details


During the first visit, participants give consent and receive physical exam. Second visit includes bronchoalveolar lavage and blood draw. The second visit will last approximately four hours.

Payment & Reimbursement


Payment Provided

Travel Reimbursement Not Available

Trial Contact


For more information, contact:

Peggy Mroz
303.398.1730

Request More Information

Trial Location


National Jewish Main Campus, Denver, CO

Trial Sponsors


National Institutes of Health

Principal Investigators

Li Li

Li Li, MD, PhD

Co-Investigators

Lisa A. Maier

Lisa A. Maier, MD, MSPH, FCCP

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required